Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why SodaStream, Intercept Pharmaceuticals, and lululemon athletica Tumbled Today

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

Stocks didn't deliver on their bullish promise on Monday, with investors focusing on negative news on the earnings front as evidence that the market might have come too far too fast in 2013 and be poised for a pullback. The broader market dropped 1% or more, but even those sizable drops were timid compared to much larger plunges in SodaStream International (NASDAQ: SODA  ) , Intercept Pharmaceuticals (NASDAQ: ICPT  ) , and lululemon athletica (NASDAQ: LULU  ) .

SodaStream nosedived 26% after releasing disappointing preliminary results for its full fiscal 2013. The company's projected adjusted earnings of $52.5 million for the year were about 20% below what many investors had expected, with sales growth slowing to its worst rate in five years despite the company posting another record year of revenue. A combination of higher costs and lower prices for its products weighed on profitability, and in light of the company's poor third-quarter performance, investors were in no mood to give SodaStream the benefit of the doubt. Going forward, the big question will be whether those who've already bought SodaStream machines will continue to build sales of flavorings and carbonator refills, a key component of the company's long-term growth plan.

Intercept fell 18%, giving back about half of its Friday gains after soaring more than 500% in two days last week. Analysts blamed the decline on Intercept's release of further data on its liver-disease therapy for nonalcoholic steatohepatitis, which pointed to the potential for higher cholesterol in patients who took the treatment. Some also noted greater awareness of liver-specialist and rival Conatus Pharmaceuticals (NASDAQ: CNAT  ) , which released its own development strategy update this morning, including plans to start a phase 2b trial on the use of its orphan-drug emricasan to treat post-orthotopic liver transplant recipients. Conatus also dropped 17% after a big rise Friday, showing the huge volatility in the space right now.

Yoga apparel specialist lululemon's 17% drop today came after its own negative guidance for the holiday quarter. With lululemon now anticipating revenue in a range that's $22 million below earlier estimates -- about 4% -- earnings are likely to come in $0.07 per share below its previous guidance. Surprisingly, the company pointed not to the pre-holiday results from December, but rather at a sluggish January in driving the poor results. Analysts point to the distractions from its quality-control issues in preventing lululemon from taking usual advantage of driving new fashions, but regardless of the cause, falling same-store sales are definitely not something shareholders are used to seeing.

Don't settle for less than the best
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2793309, ~/Articles/ArticleHandler.aspx, 8/31/2015 11:41:42 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated Moments ago Sponsored by:
DOW 16,556.08 -86.93 -0.52%
S&P 500 1,977.90 -10.97 -0.55%
NASD 4,806.73 -21.59 -0.45%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 11:22 AM
CNAT $4.07 Up +0.02 +0.49%
ICPT $189.59 Up +0.64 +0.34%
Intercept Pharmace… CAPS Rating: **
LULU $64.18 Up +1.01 +1.60%
Lululemon Athletic… CAPS Rating: ***
SODA $15.38 Up +0.47 +3.15%
SodaStream CAPS Rating: **